Highlights

  • Bioxyne shares rose 9.72% to AUD 0.079 on 12 May 2026, following the release of major corporate update.
  • Bioxyne secured a two-year AUD 50 million Supply agreement with Germany-based ADREXpharma GmbH.
  • The agreement includes a AUD 25 million minimum commitment during the first 12 months.
  • ADREXpharma received exclusive distribution rights for the Dr Watson Brand in Germany.
  • The deal expands Bioxyne’s presence in Germany, Europe’s largest medicinal cannabis market.
  • The agreement provides near-term Revenue visibility through defined supply commitments.

Bioxyne Limited (ASX:BXN) shares climbed 9.72% to AUD 0.079 during the afternoon session on 12 May 2026 after the company announced a new AUD 50 million supply agreement with German pharmaceutical company ADREXpharma GmbH.

The stock has now gained approximately 295% over the past 12 months, with investors continuing to monitor the company’s expansion across regulated medicinal cannabis and pharmaceutical markets.

The newly announced agreement will see Bioxyne, through its Wholly Owned Subsidiary Breathe Life Sciences (BLS), supply GMP-manufactured medicinal cannabis products into Germany over a two-year period.

Importantly, the agreement includes a minimum purchase commitment of AUD 25 million during the first 12 months, alongside an automatic renewal structure covering an additional 12 months. The arrangement is expected to provide Bioxyne with near-term revenue visibility while supporting further expansion into Europe.

The update also grants ADREXpharma exclusive rights to distribute Bioxyne’s Dr Watson brand within Germany.

Germany Becomes a Larger Focus for European Expansion

The latest agreement further strengthens Bioxyne’s exposure to Germany, which management described as Europe’s largest medicinal cannabis market.

Under the deal, Breathe Life Sciences will supply Australian GMP-manufactured cannabis flower and other medicinal cannabis products to ADREXpharma for distribution through its established German customer network.

The announcement represents a material expansion of the initial supply arrangement signed between the two companies in June 2025.

Management stated that increasing Demand for GMP-certified medicinal cannabis products across European markets contributed to the expansion of the Partnership.

For investors, the scale of the agreement may be particularly notable given the inclusion of defined purchase commitments and exclusive distribution rights tied to the Dr Watson brand.

Supply agreements with minimum Volume commitments can often provide greater Earnings visibility compared with shorter-term or non-exclusive arrangements.

Minimum Purchase Commitment Provides Revenue Visibility

One of the key components of the agreement is the AUD 25 million minimum commitment covering the first 12 months of the contract.

The broader agreement is valued at AUD 50 million across 24 months, with automatic renewal for the second year.

Revenue visibility is often closely monitored by investors, particularly within emerging pharmaceutical and medicinal cannabis businesses where contract stability and recurring demand can materially influence financial expectations.

The agreement structure suggests Bioxyne has secured a more established sales pathway into Germany while reducing uncertainty surrounding near-term product demand.

The company stated that supply volumes will be supported by ADREXpharma’s distribution network and existing customer relationships within Germany.

Exclusive Dr Watson Rights Expand Brand Presence

As part of the agreement, ADREXpharma has been granted exclusive rights to distribute the Dr Watson brand in Germany.

The Dr Watson brand forms part of Bioxyne’s broader international medicinal cannabis and consumer health portfolio.

Management indicated that the exclusive arrangement is intended to support targeted market penetration in Germany’s regulated medicinal cannabis market.

Brand exclusivity agreements can become strategically important within pharmaceutical and medicinal cannabis industries where distribution channels, pharmacy relationships and local market expertise influence commercial scale.

By partnering with an established local distributor, Bioxyne appears to be positioning the Dr Watson brand for broader adoption within Germany’s pharmacy and healthcare network.

European Growth Strategy Continues Expanding

Bioxyne stated that Europe, particularly Germany and the United Kingdom, remains a major focus for future growth.

The company noted that increasing patient demand and evolving regulatory frameworks continue supporting expansion opportunities across regulated international markets.

The latest agreement aligns with Bioxyne’s strategy to scale its GMP-certified Manufacturing and supply platform internationally.

While medicinal cannabis currently represents the largest commercial component of the Business, management also highlighted broader plans to expand into additional pharmaceutical products and controlled substances.

According to CEO Sam Watson, the company is actively pursuing opportunities involving both established and emerging therapeutic applications.

This suggests Bioxyne is seeking to Leverage its existing manufacturing and regulatory infrastructure as a platform for broader pharmaceutical expansion over time.

Management Commentary Highlights Long-Term Opportunity

Chief Executive Officer Sam Watson described the expanded agreement as reflective of the momentum Bioxyne is building across new markets.

Management stated that the partnership strengthens the company’s position within key regulated European markets while supporting growth across its broader pharmaceutical portfolio.

Watson also noted that ADREXpharma’s expertise in European pharmaceutical distribution made the company a suitable partner as Bioxyne explores additional therapeutic categories.

Meanwhile, ADREXpharma CEO Nicole Broockmann stated that both businesses had spent the past six months refining product quality, strengthening supply chain arrangements and establishing operational frameworks to support future growth.

According to ADREXpharma, Germany’s medicinal cannabis market is now estimated at more than 200 tonnes annually, highlighting the scale of the addressable market opportunity.

Management commentary from both companies suggests the partnership is intended to evolve beyond short-term supply arrangements into a broader scalable distribution platform.

Understanding Bioxyne’s Business Structure

Bioxyne operates as an Australian pharmaceutical company focused on the development and commercialisation of medicines and active pharmaceutical ingredients.

Through its subsidiary Breathe Life Sciences, the company has expanded into medicinal cannabis, psychedelic compounds and controlled substance manufacturing.

BLS operates as a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances, including medicinal cannabis, Psilocybin and MDMA.

The company maintains operations across multiple international markets, including Australia, the United Kingdom, Europe and Japan.

Bioxyne’s business model includes manufacturing final-dose medicines, product distribution, pharmaceutical exports and research activities involving novel medicines and alternative therapeutics.

The group also owns the Dr Watson brand across multiple jurisdictions including the United Kingdom, Australia, New Zealand and Japan.

GMP Manufacturing Capability Remains Central

A major theme within the announcement was the importance of GMP-certified manufacturing capability.

Good Manufacturing Practice (GMP) standards are a critical requirement in pharmaceutical and medicinal cannabis industries, particularly when supplying products into tightly regulated international markets such as Germany.

Bioxyne highlighted that the agreement will involve Australian GMP-manufactured products, reinforcing the company’s positioning within compliant pharmaceutical supply chains.

As European medicinal cannabis regulations continue developing, companies with established GMP infrastructure may be better positioned to secure supply agreements and regulatory approvals across multiple jurisdictions.

The latest deal therefore not only supports revenue generation but may also reinforce Bioxyne’s credibility within regulated pharmaceutical markets.

Medicinal Cannabis Demand Continues Expanding in Europe

The European medicinal cannabis market has continued evolving in recent years, with Germany remaining one of the region’s largest regulated markets.

Increasing patient adoption, expanding physician participation and evolving regulatory pathways have contributed to higher demand across parts of Europe.

Bioxyne’s latest agreement reflects ongoing international interest in medicinal cannabis supply partnerships, particularly involving GMP-certified manufacturers capable of meeting pharmaceutical standards.

The inclusion of an exclusive distribution arrangement also indicates increasing competition among suppliers seeking to establish Market Share within Europe.

What This Means for Investors

Bioxyne’s AUD 50 million agreement with ADREXpharma marks another step in the company’s international expansion strategy across regulated medicinal cannabis and pharmaceutical markets.

The minimum purchase commitment, exclusive German distribution rights and automatic renewal structure collectively provide greater near-term revenue visibility while expanding Bioxyne’s presence within Europe’s largest medicinal cannabis market.

Investors are likely to continue monitoring execution of the agreement, future European growth opportunities and the company’s broader plans to diversify into additional pharmaceutical and controlled substance categories.

The latest update also reinforces the strategic importance of GMP-certified manufacturing capability as Bioxyne continues scaling its international operations.